Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Bosutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,691Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis Scemblix ph III data first to show superior efficacy tolerability
    Novartis Scemblix ph III data first to show superior efficacy tolerability

    03 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169532&sid=2

    PHARMABIZ
    03 Jun 2024
    Share Share
    FDA approves decade-old Pfizer drug for rare childhood leukemia
    FDA approves decade-old Pfizer drug for rare childhood leukemia

    28 Sep 2023

    // Nicole DeFeudis ENDPTS

    https://endpts.com/fda-approves-decade-old-pfizer-drug-for-rare-childhood-leukemia/

    Nicole DeFeudis ENDPTS
    28 Sep 2023
    Share Share
    Amber Specialty Added to Pfizer’s Limited Distribution Network
    Amber Specialty Added to Pfizer’s Limited Distribution Network

    03 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220803005649/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share
    Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR
    Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR

    08 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/novartis-investigational-stamp-inhibitor-asciminib-abl001-shows-superior-mmr-rate-to-bosulif-in-chronic-myeloid-leukemia-trial-301188521.html

    PRNEWSWIRE
    08 Dec 2020
    Share Share
    Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary
    Novartis’ phase III ASCEMBL study of asciminib vs bosutinib meets primary

    26 Aug 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=130660&sid=2

    PHARMABIZ
    26 Aug 2020
    Share Share
    List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018
    List of Paragraph IV Patent Certifications (PPIV) as of December 3, 2018

    12 Dec 2018

    // FDA

    https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf

    FDA
    12 Dec 2018
    Share Share